reglab/housing_qa huggingface dataset:
NJ Rev Stat § 26:2A-24 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2A-24 - Definitions relative to embryo storage facilities.

26:2A-24 Definitions relative to embryo storage facilities.  2. As used in this act: "Commissioner" means the Commissioner of Health. "Department" means the Department of Health. "Embryo storage facility" means a facility which cryopreserves and stores human eggs, pre-embryos, and embryos for later use in in vitro fertilization, embryo transfer, gamete transfer, pronuclear stage transfer and zygote transfer, and other procedures performed to achieve a pregnancy or pregnancies. Embryo storage facility shall also include the office of a licensed health care provider which stores human eggs, pre-embryos, or embryos. "Person" means any individual, corporation, company, association, organization, society, firm, partnership, joint stock company, or the State or any political subdivision thereof. L.2019, c.268, s.2.
NJ Rev Stat § 26:2A-25 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2A-25 - Licensure for embryo storage facility.

26:2A-25 Licensure for embryo storage facility.  3. a. No person shall conduct, maintain, or operate an embryo storage facility in this State unless licensed by the department pursuant to the provisions of this act. A separate license shall be required for each embryo storage facility location. The license shall be posted and displayed at all times in a prominent location within the facility. No license issued pursuant to this act shall be transferable. A change in the ownership of the facility shall require notification to the department within 14 calendar days and reapplication for licensure. b. The department shall not license a person to conduct, maintain, or operate an embryo storage facility pursuant to this act unless the department is satisfied that the person has demonstrated good character, competency, and integrity, and has furnished such information to the commissioner as the commissioner may require for this purpose. L.2019, c.268, s.3.
NJ Rev Stat § 26:2A-26 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2A-26 - Rules, regulations.

26:2A-26 Rules, regulations.  4. a. The department shall promulgate rules and regulations pursuant to the "Administrative Procedure Act," P.L.1968, c.410 (C.52:14B-1 et seq.) governing the storage and care of human eggs, pre-embryos, and embryos by an embryo storage facility in accordance with: (1) Standards ISO 9001 and ISO 20387 of the International Organization for Standardization; (2) standards for biorepositories established by the College of American Pathologists Biorepository Accreditation Program; and (3) the U.S. Food and Drug Administration guidance on Current Good Tissue Practices. b. The rules and regulations promulgated pursuant to this section shall promote safety and best practices among embryo storage facilities and, at a minimum: prescribe standards governing the operation, maintenance, and administration of embryo storage facilities; the safety and adequacy of the physical plant or the facilities; compliance with State and local fire safety codes; the number of staff and the qualifications of each staff member; the protection and safety of the equipment used by embryo storage facilities to process and store human eggs, pre-embryos, and embryos; the maintenance and confidentiality of records and furnishing of required information; the maintenance of all appropriate accreditations and certifications; the establishment of a quality management program; and the review of the scope of internal audits.  c. The department shall conduct an on-site facility inspection and shall evaluate the embryo storage facility to determine whether the facility complies with the provisions of this act. d. The department shall have the authority to inspect and examine the physical plant or facilities of an embryo storage facility and to inspect all documents, records, files, or other data maintained pursuant to this act during normal operating hours and without prior notice. e. The department shall request the appropriate State and local fire, health, and building officials to conduct examinations and inspections to determine compliance with State and local ordinances, codes, and regulations by an embryo storage facility. The inspections shall be conducted and the results reported to the department within 60 days after the request. f. If an embryo storage facility meets the requirements of this act and the rules and regulations promulgated hereunder, the department shall issue a license to the facility. A license shall be valid for a period of one year and may be renewed at the end of that period, subject to continued compliance with the provisions of this act. g. Nothing in this section shall be interpreted to permit the adoption of any code or standard which exceeds the standards established pursuant to the "State Uniform Construction Code Act," P.L.1975, c.217 (C.52:27D-119 et seq.). L.2019, c.268, s.4.
NJ Rev Stat § 26:2A-27 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2A-27 - Application for licensure.

26:2A-27 Application for licensure.  5. Any person operating an embryo storage facility on or after the effective date of this act or desiring to operate an embryo storage facility shall make application for licensure in a manner and on forms prescribed by the commissioner. The license application form shall include, but shall not be limited to, the following information: a. the name and address of the embryo storage facility b. a description of the facility's premises and facilities and the hours of its operation; and c. any other information the commissioner deems necessary to include on the license application form. L.2019, c.268, s.5.
NJ Rev Stat § 26:2A-28 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2A-28 - Fees for licensure.

26:2A-28 Fees for licensure.  6. a. The commissioner shall establish a minimum fee to be paid by each embryo storage facility at the time of application for a license and at every renewal of a license. b. The income received from licensure and renewal fees pursuant to this section shall be appropriated to the department to effectuate the purposes of this act. L.2019, c.268, s.6.
NJ Rev Stat § 26:2A-29 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2A-29 - Denial, suspension, revocation, refusal to renew license.

26:2A-29 Denial, suspension, revocation, refusal to renew license.  7. The department may deny, suspend, revoke, or refuse to renew a license for good cause, including, but not limited to: a. Failure of an embryo storage facility or its operator to comply with the provisions of this act; b. Violation of the terms and conditions of a license by an embryo storage facility or its operator; c. Use of fraud or misrepresentation by an embryo storage facility or its operator in obtaining a license or in the subsequent operation of the facility; d. Refusal by an embryo storage facility or its operator to furnish the department with required files, reports, or records; or e. Refusal by an embryo storage facility or its operator to permit an inspection by an authorized representative of the department during normal operating hours. L.2019, c.268, s.7.
NJ Rev Stat § 26:2A-30 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2A-30 - Notice, hearing.

26:2A-30 Notice, hearing.  8. a. The department, before denying, suspending, revoking, or refusing to renew a license, shall give notice to the operator personally, or by certified or registered mail to the last known address of the operator with return receipt requested. The notice shall afford the operator with an opportunity to be heard in person or by an attorney, and to offer evidence pertinent to the subject of the hearing. b. The hearing shall take place within 60 days from the issuance or mailing of the notice and shall be conducted in accordance with the "Administrative Procedure Act," P.L. 1968, c.410 (C.52:14B-1 et seq.). L.2019, c.268, s.8.
NJ Rev Stat § 26:2A-31 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2A-31 - Violations, third degree crime.

26:2A-31 Violations, third degree crime.  9. Any person who operates or assists in the operation of an embryo storage facility which does not have a license, who has used fraud or misrepresentation in obtaining a license or in the subsequent operation of a facility, who offers, advertises, or provides any service not authorized by a valid license, or who violates any other provision of this act, shall be guilty of a crime of the third degree. L.2019, c.268, s.9.
NJ Rev Stat § 26:2AA-1 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2AA-1 - Short title.

26:2AA-1 Short title.  1. This act shall be known and may be cited as the "Reflex Sympathetic Dystrophy Syndrome Education and Research Program Act." L.2007, c.255, s.1.
NJ Rev Stat § 26:2AA-2 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2AA-2 - Findings, declarations relative to reflex sympathetic dystrophy syndrome (RSDS) education and research program.

26:2AA-2 Findings, declarations relative to reflex sympathetic dystrophy syndrome (RSDS) education and research program.  2. The Legislature finds and declares that: a. Reflex sympathetic dystrophy syndrome (RSDS), also known as complex regional pain syndrome, is a debilitating and progressively chronic condition characterized by severe burning pain, pathological changes in bone and skin, excessive sweating, tissue swelling and extreme sensitivity to touch; b. More specifically, RSDS is thought to be a nerve disorder that generally occurs at the site of a minor or major trauma injury, but may also occur without an apparent injury to the afflicted person; c. While the causes of RSDS are unknown, the syndrome is thought to be the result of damaged nerves of the sympathetic nervous system;  d. The disorder is unique in that it simultaneously affects the nerves, skin, muscles, blood vessels and bones, and if untreated, can result in permanent deformity and chronic pain;  e. RSDS is often misdiagnosed because this condition is either unknown or is poorly understood; the prognosis for patients suffering from RSDS is generally much better when the condition is identified and treated as early as possible, ideally within three months of identifying the first symptoms;  f. If treatment is delayed, the disorder can quickly spread to the entire limb, and changes in bone and muscle may become irreversible, resulting in limited mobility, atrophy of the muscles and eventual permanent disability of patients; and  g. Since a delay in diagnosis or treatment for this syndrome can result in severe physical and physiological problems, and early recognition and prompt treatment of RSDS provides the greatest opportunity for recovery, it is in the best interest of the public to establish a program to educate both individuals and medical professionals regarding this debilitative condition and to promote research to accurately identify, diagnose and treat RSDS.  L.2007, c.255, s.2.
NJ Rev Stat § 26:2AA-3 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2AA-3 - Definitions relative to RSDS.

26:2AA-3 Definitions relative to RSDS.  3. As used in this act: "Commissioner" means the Commissioner of Health; and "Reflex sympathetic dystrophy syndrome" or "RSDS" means a debilitating and progressively chronic condition characterized by severe burning pain, pathological changes in bone and skin, excessive sweating, tissue swelling, and extreme sensitivity to touch.  L.2007, c.255, s.3; amended 2012, c.17, s.144.
NJ Rev Stat § 26:2AA-4 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2AA-4 - Establishment of education and research program.

26:2AA-4 Establishment of education and research program.  4. The commissioner shall establish a reflex sympathetic dystrophy syndrome education and research program in the Department of Health. The purpose of the program is to promote public awareness of the causes of RSDS, the value of early detection and the diagnosis of and possible treatments for the syndrome, and to promote research, through public and private sources, to accurately identify, diagnose, and treat RSDS. L.2007, c.255, s.4; amended 2012, c.17, s.145.
NJ Rev Stat § 26:2AA-5 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2AA-5 - Responsibilities of Department of Health.

26:2AA-5 Responsibilities of Department of Health.  5. The Department of Health shall: a. establish a public education program through the department's website, to promote RSDS education, which will enable individuals to make informed decisions about their health, including, but not limited to the following elements: (1) the cause and nature of RSDS; (2) the risk factors that contribute to the manifestation of RSDS; (3) available treatment options, including risks and benefits of those options;  (4) environmental safety and injury prevention; (5) rest and use of appropriate body mechanics; (6) the availability of RSDS diagnostic, treatment, and outreach services in the community; and (7) any other factors or elements that might mitigate the effects of RSDS; b. notify local health departments, hospitals, clinics, and other health care providers about the availability of information concerning RSDS on the department's website; c. within the limits of funds available to the department for this purpose, coordinate, promote, and offer professional education programs, through institutions of higher education, for health care providers and health-related community-based organizations, which may include, but are not limited to the following elements: (1) research findings; (2) the cause and nature of RSDS; (3) the risk factors, including, but not limited to, lifestyle, heredity, and drug interactions; (4) the diagnostic procedures and appropriate indications for their use; (5) medical and surgical treatment options, including experimental and established drug therapies and the risks and benefits of each option; (6) environmental safety and injury prevention; and (7) the availability of RSDS diagnosis and treatment and support services in the community; and d. promote research, through both private and public funding sources, to accurately identify, diagnose, and treat RSDS. L.2007, c.255, s.5; amended 2012, c.17, s.146.
NJ Rev Stat § 26:2AA-6 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2AA-6 - Powers of commissioner concerning funding.

26:2AA-6 Powers of commissioner concerning funding.  The commissioner may accept and expend any grants, awards or other funds or appropriations as may be made available for the purposes of this act. L.2007, c.255, s.6.
NJ Rev Stat § 26:2AA-7 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2AA-7 - Findings, declarations relative to orphan disease.

26:2AA-7 Findings, declarations relative to orphan disease.  1. The Legislature finds and declares: a. A rare disease is defined as a disease that affects fewer than 20,000 people. Rare diseases are sometimes called orphan diseases. There are 7,000 rare diseases affecting approximately 25 to 30 million Americans; b. The exact cause for many rare diseases remains unknown. However, 80 percent of rare diseases are genetic in origin and can be linked to mutations in a single gene or in multiple genes which can be passed down from generation to generation; c. A person suffering with a rare disease faces a wide range of challenges, including delays in obtaining a diagnosis; being misdiagnosed; shortages of medical specialists who can provide treatment for rare diseases; and the lack of therapies and medication that are used by doctors to treat rare diseases; d. There is a significant link between rare disease and the coronavirus 2019 (COVID-19) pandemic which heightens the importance of the establishment of an advisory council to examine the issues that affect persons with rare diseases in the State. Many people who live with rare diseases are immunosuppressed and have respiratory and neurologic issues that make the consequences of the virus much more severe for them; e. Additionally, those with rare diseases rely on the health care system much more than those who do not have chronic and rare conditions. In as much as they go to their physicians' offices, medical testing sites, and hospitals more often than most, their risk of exposure to the COVID-19 virus is much greater; f. People who live with rare diseases are impacted by potential shortages of life-saving medications and supplies due to changes in supply chain resulting from the COVID-19 pandemic. People with rare diseases also rely on the support of their families and home health aides, and because of the social distancing and quarantining, the pandemic puts them at risk of not having the support they need in accessing services and treatment; g. Researchers have made considerable progress in developing diagnostic tools and treatment protocols for rare diseases and discovering methods of prevention. However, much more remains to be done in the search for new therapeutics and in understanding the link between rare disease and pandemics, and h. It is therefore an appropriate public policy for the State of New Jersey to establish an advisory body, whose membership would be comprised of qualified professionals and persons living with rare diseases, that would be tasked to educate medical professionals, government agencies, and the public about the importance of rare diseases as an important public health issue, and to encourage research in the development of new treatments for rare diseases. L.2021, c.135, s.1.
NJ Rev Stat § 26:2AA-9 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2AA-9 - Purpose of council.

26:2AA-9 Purpose of council.  3. The purpose of the advisory council shall be to: a. act as the advisory body on rare diseases to the Legislature and State departments, agencies, commissions, authorities, and private agencies that provide services to, or are charged with the care of, persons with rare diseases; b. conduct a thorough and comprehensive study of all issues relating to the quality of and access to treatment and services provided to persons with rare diseases in this State, including the link between rare diseases and the COVID-19 pandemic, and to develop policy recommendations on those issues; c. develop recommendations for best practice standards encompassing the most effective strategies for recognizing and treating rare diseases in New Jersey; d. identify effective research-based strategies that have been developed to help diagnose, treat, and prevent rare diseases;  e. develop effective strategies to raise public awareness of rare diseases in this State; f. evaluate and make recommendations to improve: (1) the State's Newborn Screening Program in the Department of Health; and (2) State Medicaid coverage for approved treatments and medications for patients with a rare disease; g. research and make policy recommendations to the Legislature on access to health insurance specialists and other needed services for patients with a rare disease; and h. identify, with assistance from the public, additional research topics on rare disease to inform future studies the council may conduct. L.2021, c.135, s.3.
NJ Rev Stat § 26:2AA-10 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2AA-10 - Report to Governor, Legislature.

26:2AA-10 Report to Governor, Legislature.  4. The advisory council shall report to the Governor and, pursuant to section 2 of P.L.1991, c.164 (C.52:14-19.1), to the Legislature, no later than December 31st, on a biennial basis, starting in the second year next following the enactment of this act, on the activities of the advisory council and its findings and recommendations on issues relating to the quality of, and access to, treatment and services for persons with rare diseases in this State. L.2021, c.135, s.4.
NJ Rev Stat § 26:2B-6 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2B-6 - Commission on Alcoholism and Promotion of Temperance abolished

26:2B-6. Commission on Alcoholism and Promotion of Temperance abolished  The Commission on Alcoholism and Promotion of Temperance established by "An act concerning the preparation and administration of a program for the rehabilitation of alcoholics and the promotion of temperance education by the Commissioner of Alcoholic Beverage Control, the Commissioner of Institutions and Agencies, the Commissioner of Education and the Director of Health constituted the Commission on Alcoholism and Promotion of Temperance," approved April fourth, one thousand nine hundred and forty-five (P.L.1945, c. 94), is abolished. L.1948, c. 453, p. 1856, s. 6.
NJ Rev Stat § 26:2B-7 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2B-7 - Public policy.

26:2B-7 Public policy.  1. It is the policy of the State of New Jersey that persons with an alcohol use disorder and intoxicated persons may not be subjected to criminal prosecution because of their consumption of alcoholic beverages, but rather should be afforded a continuum of treatment in order that they may lead lives as productive members of society. L.1975, c.305, s.1; amended 2017, c.131, s.69.